LIVE: WHO chief, experts brief media on Ebola outbreak

Key Concepts

• Bundjo Virus (Ebola): A rare strain of the Ebola virus causing the current outbreak.
• One Health Agenda: An integrated approach to health that recognizes the connection between people, animals, and the environment, particularly regarding zoonotic diseases.
• Clinical Trials: Research studies to evaluate the safety and efficacy of vaccines and therapeutics.
• Contact Tracing: The process of identifying, assessing, and managing people who have been exposed to a disease to prevent onward transmission.
• Medical Countermeasures: Vaccines, therapeutics, and diagnostics used to prevent or treat a disease.
• Zoonotic Disease: An infectious disease that has jumped from a non-human animal to humans.
• IHR (International Health Regulations): A set of rules to prevent, protect against, and control the international spread of disease.

---

1. Current Situation and Epidemiological Data

• Outbreak Status: The outbreak is centered in the Democratic Republic of the Congo (DRC), specifically in the Ituri, North Kivu, and South Kivu provinces.
• Statistics: 344 confirmed cases and 60 deaths across 24 health zones.
• Backlog Management: The number of suspected cases dropped from over 1,000 to 116 as teams cleared the backlog of testing.
• International Spread: One confirmed death and 15 cases in Uganda, including a traveler who visited the UAE. A US citizen infected in the DRC is receiving care in Germany.
• Risk Assessment: Very high at the national level, high at the regional level, and low at the global level.

2. Response Framework and Challenges

• Operational Strategy: The WHO emphasizes "One plan, one budget, one report" under the leadership of the DRC government.
• Key Challenges:
  • Insecurity: Armed conflict and displacement (over 100,000 newly displaced) hinder response efforts.
  • Community Mistrust: Significant barriers exist due to beliefs that Ebola is not real or is a fabrication by foreign forces.
  • Diagnostic Delays: Efforts are underway to decentralize laboratory capacity to reduce confirmation times.
  • Contact Tracing: Currently at 45%; the target is to exceed 90% to gain control of the outbreak.
  • Travel Restrictions: The WHO advises against blanket travel restrictions, recommending exit screening at borders instead.

3. Medical Countermeasures and Research

• Vaccines: Three candidates are in development. Moderna and the Oxford/Serum Institute of India vaccines are the most advanced, with clinical trials expected in 2–3 months. The IAVI candidate is estimated to take 7–9 months.
• Therapeutics: Clinical trials are being integrated into case management. Key agents include MBP134 (a pan-Ebola monoclonal antibody) and Remdesivir.
• Oral Antivirals: Research is focusing on an oral antiviral for post-exposure prophylaxis, which could be a significant tool for contact tracing.

4. Financial and Logistical Needs

• Funding: The initial three-month response requires $115 million. Currently, the effort is only 35% funded.
• Logistics: The WHO has deployed 106 staff, with plans to scale up to 278. Mobile laboratories have been deployed to key locations like Mongualu to improve diagnostic speed.

5. Notable Quotes

• Dr. Tedros Adhanom Ghebreyesus: "The key to ending this outbreak is not biomedical. It's leadership, ownership, partnership, and trust."
• Dr. Tedros Adhanom Ghebreyesus: "Our ultimate measure of success is not whether we stop this outbreak. We will... The real measure of success is what we do to prevent the 18th outbreak and the 19th."
• Dr. Chu Ehuazu: "Partners are working ahead of the resources and really anticipating that as usual the world will come together not as an act of charity but as an act of solidarity."

6. Synthesis and Conclusion

The Ebola outbreak caused by the Bundjo virus is a complex emergency exacerbated by regional conflict, community mistrust, and the rarity of the viral strain. While the WHO and the DRC government are scaling up diagnostic and treatment capacities, the response is currently hampered by funding gaps and security issues. The WHO’s strategy focuses on decentralized diagnostics, community engagement, and the rapid advancement of clinical trials for vaccines and therapeutics. Ultimately, the organization stresses that while biomedical tools are essential, long-term success depends on strengthening local health systems and addressing the zoonotic root causes of the disease to prevent future outbreaks.